Eli Lilly has launched Lormalzi in India, introducing a once-monthly Alzheimer’s therapy aimed at slowing cognitive and functional decline in patients at the early symptomatic stage of the disease.
The treatment, also known as donanemab, has been priced at ₹91,688 for a 350 mg vial and is expected to become available through hospitals and pharmacies this month. It is administered as an intravenous infusion once every four weeks and is intended for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, where amyloid pathology has been confirmed.
Lormalzi targets amyloid plaques, the abnormal protein deposits in the brain associated with Alzheimer’s progression. The therapy is designed to help clear excessive amyloid build-up and slow the decline that can affect memory, planning, decision-making and day-to-day independence. Unlike symptom-management medicines that aim to improve cognition temporarily, donanemab belongs to a newer class of disease-modifying treatments that seek to intervene in the biological process linked to the condition.
The launch follows marketing authorisation from the Central Drugs Standard Control Organization, which cleared donanemab for adults in the early symptomatic stages of Alzheimer’s disease. The approval covers patients with mild cognitive impairment and those in the mild dementia stage, making diagnosis and patient selection central to its use. Access will depend not only on affordability but also on specialist evaluation, amyloid confirmation, infusion capacity and monitoring for potential adverse effects.
Lilly’s India leadership has presented Alzheimer’s disease as a core part of the company’s specialty medicines strategy, alongside obesity and metabolic disorders. Winselow Tucker, president and general manager of Eli Lilly and Company, has said the company plans an alternative access programme to widen availability for eligible patients. The company has also emphasised that treatment is not lifelong, with therapy continuing for up to 18 months depending on clinical assessment and amyloid reduction.
The introduction comes as dementia poses a growing health challenge in the country. About 8.8 million people are estimated to be living with dementia, with Alzheimer’s disease accounting for most cases. That figure is projected to rise sharply by 2036 as life expectancy increases and awareness remains uneven. Delayed diagnosis, stigma, limited memory clinics and high out-of-pocket expenditure continue to restrict timely intervention.
Lormalzi’s monthly dosing gives Lilly a commercial and clinical differentiator in a field where competing amyloid-targeting therapies have also drawn attention. The drug is marketed under the Kisunla brand in several markets, including the United States, where regulators cleared it for early symptomatic Alzheimer’s disease. Its evidence base includes late-stage trial data showing a slowing of cognitive and functional decline over 18 months in selected patients.
The therapy, however, enters the market with important safety and implementation considerations. Amyloid-targeting antibodies can cause amyloid-related imaging abnormalities, including brain swelling and bleeding. Many cases may be asymptomatic, but serious and life-threatening events have been reported in this drug class. Patients generally require baseline assessment, specialist supervision and periodic brain imaging, which could limit wider use beyond major neurology centres.
Cost will be another major factor. At ₹91,688 per vial, the monthly drug price alone places Lormalzi beyond the reach of many households without insurance cover, institutional support or company-backed access assistance. Additional expenses may include diagnostic scans, amyloid testing, infusion services, physician visits and safety monitoring. The overall treatment burden will therefore depend on how hospitals, payers and patient-support programmes structure access.
The launch also reflects a broader shift in Alzheimer’s care from symptomatic treatment to biological intervention, but the transition will test the readiness of the healthcare system. Early-stage diagnosis remains difficult because memory complaints are often dismissed as normal ageing, while specialist referral may occur only after functional impairment has advanced. Disease-modifying therapies work best in the earlier window, making awareness among families, primary-care doctors and neurologists critical.
